Argitalpenak (114) Ikertzaileren baten partaidetza izan duten argitalpenak

2023

  1. A Multimodal Scaffold for SDF1 Delivery Improves Cardiac Function in a Rat Subacute Myocardial Infarct Model

    ACS Applied Materials and Interfaces, Vol. 15, Núm. 44, pp. 50638-50651

  2. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

    The Lancet Haematology, Vol. 10, Núm. 2, pp. e117-e128

  3. AG5 is a potent non-steroidal anti-inflammatory and immune regulator that preserves innate immunity

    Biomedicine and Pharmacotherapy, Vol. 169

  4. Alginate and collagen-based hydrogel: a novel cardiactherapeutic platform for extracellular vesicle delivery

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  5. Alginate sulfate-nanoparticles loaded with hepatocyte growth factor and insulin-like growth factor-1 improve left ventricular repair in a porcine model of myocardial ischemia reperfusion injury

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 184, pp. 83-91

  6. An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration

    npj Regenerative Medicine, Vol. 8, Núm. 1

  7. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

    Leukemia and Lymphoma

  8. Analysis of common biomarkers in capillary blood in routine clinical laboratory. Preanalytical and analytical comparison with venous blood

    Diagnosis, Vol. 10, Núm. 3, pp. 281-297

  9. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

    Leukemia Research, Vol. 129

  10. Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 12, pp. 3581-3588

  11. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  12. Biología celular del cáncer

    Biología celular biomédica (Elsevier), pp. 375-407

  13. CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

    Hematology, Transfusion and Cell Therapy, Vol. 45, Núm. 2, pp. 266-274

  14. CC-Chemokine Receptor-2 Expression in Osteoblasts Contributes to Cartilage and Bone Damage during Post-Traumatic Osteoarthritis

    Biomolecules, Vol. 13, Núm. 6

  15. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  16. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  17. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 7

  18. Cardiac Progenitor Cell Exosomal miR-935 Protects against Oxidative Stress

    Cells, Vol. 12, Núm. 18

  19. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70

  20. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries

    Frontiers in Medicine, Vol. 10